WO2021067930A1 - Tumor-targeting polypeptide nanoparticle delivery system for nucleic acid therapeutics - Google Patents

Tumor-targeting polypeptide nanoparticle delivery system for nucleic acid therapeutics Download PDF

Info

Publication number
WO2021067930A1
WO2021067930A1 PCT/US2020/054251 US2020054251W WO2021067930A1 WO 2021067930 A1 WO2021067930 A1 WO 2021067930A1 US 2020054251 W US2020054251 W US 2020054251W WO 2021067930 A1 WO2021067930 A1 WO 2021067930A1
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
composition
nucleic acid
sirna
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2020/054251
Other languages
English (en)
French (fr)
Inventor
Xiaoyong Lu
Patrick Y. Lu
David M. Evans
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sirnaomics Inc
Original Assignee
Sirnaomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020227014303A priority Critical patent/KR20220110174A/ko
Priority to AU2020357078A priority patent/AU2020357078A1/en
Priority to IL291916A priority patent/IL291916A/en
Priority to CN202080084185.2A priority patent/CN115151278B/zh
Priority to JP2022520803A priority patent/JP7644105B2/ja
Priority to EP20872228.0A priority patent/EP4037716A4/en
Application filed by Sirnaomics Inc filed Critical Sirnaomics Inc
Priority to BR112022006473A priority patent/BR112022006473A2/pt
Priority to CA3156823A priority patent/CA3156823A1/en
Publication of WO2021067930A1 publication Critical patent/WO2021067930A1/en
Anticipated expiration legal-status Critical
Priority to US17/713,037 priority patent/US20220331441A1/en
Priority to ZA2022/04734A priority patent/ZA202204734B/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/641—Branched, dendritic or hypercomb peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/127—DNAzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers

Definitions

  • Delivery systems for nucleic acids and methods of use are provided, including methods for targeted delivery or local delivery of nucleic acid molecules.
  • Targeted delivery of therapeutics has attracted great interest and benefit to improve tumor treatment through increasing efficacy and reduced side effects. It is believed that accumulation of the nanoparticles (NPs) in tumors is by enhanced permeability and retention (EPR) effect (Maeda, Bioconjugate Chemistry, 21:797-802 (2010)). Thus, the tumor delivery can be improved by coating the particle with tumor -localizing ligands. The mechanism by which ligands increase the antitumor efficacy of their cargo (such as siRNA) is still under debate. Enhanced binding to the tumor surface marker can increase accumulation of NPs in the tumor compared to that of nontargeted tissue. Other investigators have claimed that accumulation of targeted and nontargeted NPs within tumor cells was comparable.
  • siRNA in vivo has been challenging due to their degradation by serum nucleases and rapid clearance, endosomal entrapment, and innate immunity simulation by the nanoparticles (NPs).
  • NPs nanoparticles
  • GalNAc-siRN A conjugates in which a synthetic triantennary N- acetylgalactosamine-based ligand (GaLNAc) is conjugated to chemically modified siRNA. This has enabled efficient, ASGPR-mediaied delivery to hepatocytes. Maja et al.; Nature Communications, 9:723 (2016).
  • GaLNAc targets the hepatoeyte-specific asialoglycoprotein receptor (ASGPR) in liver.
  • ASGPR asialoglycoprotein receptor
  • APN-AT3 phase II clinical trial, Alnylam
  • RBDs hemophilia and rare bleeding disorders
  • RNAi therapeutic aims to target anti thrombin (AT).
  • the targeting ligand has been incorporated into a liposome formulation when multiple components have been co-assembled together with the siRNA. This Ape of system retains many of the challenges in terms of the stabilit>' of the liposome, biocompatibility toxicity, production and long term storage in large scale. Leng et al, J.
  • FIG. 1 Tumor Targeting HKC/HKP or HKP(+H) Polypeptide Nanoparticle Delivery System.
  • the graph shows that the formation of a tumor targeting polypeptide nanoparticle between (A) a branched polypeptide H3K4B (HKP) or H3K(+H)4b or (HKP(+H)) with specific histidine/lysine sequence, (B) a linear polypeptide functionalized through a terminal cysteine with a tumor targeting ligand such as RGD, folate, or SmAb, etc. and selected siRNA, and its HKC polypeptide-siRNA nanoplex formation.
  • a tumor targeting polypeptide nanoparticle between (A) a branched polypeptide H3K4B (HKP) or H3K(+H)4b or (HKP(+H)) with specific histidine/lysine sequence, (B) a linear polypeptide functionalized through a terminal cysteine with a tumor targeting ligand such as RGD,
  • HKC HKC1, HKC2 or HK2C see Figure 3
  • HKC bears a terminal cysteine was conjugated with a Maleimide functionalized PEG linked targeting motif such as (folate, RGD, mAb, etc.) through thiol/maleimide addition reaction under a mild condition.
  • FIG. 1 Structure of H3K4b (HKP in abbreviation) branched peptide, structure of the H3K4C (in abbreviation HKC1 or HKC) with one cysteine at the terminal site, and structure of HKC2 with two cysteine in the sequence.
  • HKC1 or HKC structure of the H3K4C with one cysteine at the terminal site
  • HKC2 structure of HKC2 with two cysteine in the sequence.
  • FIG. 3C Mass spectroscopy (ESI-MS, positive) of the HKC1 compound, observed double charged molecular ion peak at 1335.6 [M] 2+ .
  • Figure 4. Shows the preparation route of HKC2-Pegiooo-folate, HKC1 was reacted with Maleimide-PEG-folate through the thiol/maleimide addition reaction under basic condition to provide the conjugation product. After remove the solvent then purification by dialysis, the HKCl-Pegiooo-folate was obtained.
  • FIG. 1 Characterization of HKC2-PEGlk-folate by 'H NMR, (top) HKC2 in D2O, and (middle) HKC2-PEGlk-folate in DMSO-d6,. and (bottom) folate-PEGlk-Mal.
  • the HKC was covalently coupled with folate-PEGlk-Mal, the characteristic signal of maleimide double bond at 7.0 ppm was disappeared after reacted with cysteine.
  • Figure 6 Shows the UV/Vis (water, 25 °C) spectroscopy of HKC2-PEGlk-folate (top red curve) and Folate-PEGlk-Mal (bottom gray curve) in water. The characteristic absorbance at the 220nm for the peptide and 275 nm for the folate was observed in the product spectrum.
  • Figure 7 Shows the MALDI-MS (positive) spectroscopy of the HKC2-PEGlk-folate, the molecular ion peak around 4302 M + indicates that the successful conversion of the HKC2 from the coupling reaction.
  • Figure 8 Shows the preparation of HKC2-PEG2k-RGD in two steps.
  • the first step the coupling between c(RGDfk) and a bifunctional PEG molecule bearing N- hydroxySuccinimide (NHS) and Maleimide (Mai) functional groups, forming an amide bond through the coupling between amine and NHS.
  • the second step the thiol in HKC was reacted with maleimide of RGD-PEG2000-Mal to provide the RGD attached PEG linker polypeptide HKC2-PEG2000-RGD.
  • FIG. 9 Shows the characterization of RGD-PEG2k-Mal intermediate by 3 ⁇ 4 NMR (DMSO-d6 , 25 °C) spectroscopy. We can observe the RGD signals at 8.5-7.2 ppm and maleimide signal at 7.00 ppm, PEG ethylene broad peak at ⁇ 3.5 ppm.
  • Figure 10 Shows the stack plot comparison of the characterization of HKC2-PEG- RGD by 'H NMR spectroscopy HKC2 derivatization with RGD targeting ligand.
  • HKC HKC:HKP:TGF ⁇ 1 in the formation of nanoparticle and its size distribution.
  • Figure 13 Formulation of HKC:HKP:TGF ⁇ 1 in the formation of nanoparticle and its polydispersity index.
  • FIG. 14 Effect of treatment with Cell Death siRNA formulated with HKP alone or in combination with various amount of HKP and HKC2 on human glioblastoma T98G cells viability.
  • a aqueous solution of HKC2 (160 ng/ ⁇ L), HKP (320 ng/pL) and siRNA (80 ng/ ⁇ L) was mixed in the defined ratio and incubated at RT for 30 min.
  • Transfection complexes were diluted with OPTI-MEM and added to the cells in 100 pL medium supplied with fresh medium. Transfection medium was replaced with 10% FBS/DMEM or EMEM in 6h after. At 72h post-transfection number of viable cells was assessed with CellTiter-Glo Luminescent cell viability assay (Promega). Values derived from untreated cells (Blank) were set as 100%. All values represent the mean of ⁇ S.D. of four replicates NS-non-silencing siRNA, CD-Cell Death siRNA.
  • FIG. 15 Effect of treatment with Cell Death siRNA formulated with HKP alone or in combination with various amount of HKP and HKC2 on human hepatocellular carcinoma HepG2 cells viability.
  • An aqueous solution of mixture of HKC2 (160 ng/ ⁇ L), HKP (320 ng/ ⁇ L) and siRNA (80 ng/ ⁇ L) was incubated at RT for 30 min.
  • Transfection complexes were diluted with OPTI-MEM and added to the cells in 100 pL medium supplied with fresh medium. Transfection medium was replaced with 10% FBS/DMEM or EMEM in 6h after. At 72h post-transfection number of viable cells was assessed with CellTiter-Glo Luminescent cell viability assay (Promega). Values derived from untreated cells (Blank) were set as 100%. All values represent the mean of ⁇ S.D. of four replicates NS-non-silencing siRNA, CD- CellDeath siRNA.
  • FIG. 16 Formulation and nanoparticle formation through self-assembly among HKC2-PEGlk-folate, H3K4b (HKP) and siRNA.
  • TGF ⁇ 1 was used in 80 ng/ ⁇ L in water and mixed with equal volume of the HKC and HKP in water.
  • FIG. 1 Polydispersity index of nanoparticle formation through self-assembly among HKCl-PEG-folate, H3K4b (HKP) and siRNA.
  • TGF ⁇ 1 80 ng/ ⁇ L in water was mixed with equal volume of the HKC and HKP in water.
  • HBP histidine(H)-lysine(K) rich polypeptide
  • H3K branched repeating
  • HKC targeting ligand at the terminal site
  • compositions and methods are provided for delivering nucleic acid to target cells of interest.
  • the composition comprises a branched polypeptide (HKP) and linear peptide (HKC).
  • this composition includes one or more nucleic acid.
  • the compositions include a pharmaceutically acceptable carrier.
  • a four branched histidine-lysine rich polypeptide is used in the formulation with a linear peptide having certain structure and functional properties to be an effective carrier for: a) target nucleic acids to one or more particular cell types and b) delivery of the targeted nucleic acids to the particular intracellular location.
  • the linear peptide contains a cell specific targeting ligand (e.g., a small molecule, or cyclic peptide-based homing domain), which is conjugated with a positively charged linear HKC peptide that both binds to nucleic acid and provide the cell directing and transporting properties to help deliver the nucleic acid to the cytosol of the targeted cell.
  • methods are provided to conjugate a targeting ligand to the delivery carrier by a direct covalent linkage strategy.
  • the targeting ligand e.g. folate, RGD or a peptide
  • This method provides a versatile platform to introduce various targeting ligands to the delivery system for protecting the target nucleic acids.
  • the chemical conjugation between the positive charged peptide HKC and the ligand can be disulfide bond, sulfur-carbon bond from thiol/maleimide, or any other covalent bonds or biodegradable bonds like hydrazine and amide, but not necessarily limited to this type.
  • novel methods are provided for nanoparticle formulation of a polypeptide (HKP), a linear peptide bearing a targeting ligand, and an siRNA for tumor targeting.
  • the nucleic acid is delivered in complex that includes a targeting linear polypeptide comprising a motif that binds to a cellular target and a branched polypeptide.
  • the two peptides were formulated in a defined ratio in a mixture with target nucleic acid in a nanoparticle formation.
  • the ratio of the negative charge (e.g. from the nucleic acid) to positive charge (e.g., in the peptide and polypeptide) of a peptide/nucleic acid complex can impact the strength of the non-cell-specific transduction properties of the complex.
  • compositions and methods are provided for delivering one or more nucleic acids to cellular targets.
  • one or more nucleic acid was delivered in a nanoparticle at the same time.
  • the chemotherapy drug can be co-formulated within the nanoparticle complex. This provides the advantage and benefit in combinational therapy for treatment of the tumor.
  • these and other aspects provide a delivery platform that is a system into which can be introduced any type of targeting motif to target any cell of interest.
  • a stepwise method of conjugation a target ligand to peptide through a linker has been developed and presented in the application.
  • the various targeting ligands provide specific transduction properties to any type of the cell of interest.
  • the binding domain in the peptide which has HK positive repeating units, it binds to the negative charged nucleic acid through hydrogen bond between the histidine and phosphate, and ion-ion interaction between the protonated lysine and phosphonate. The nucleic acid was protected and delivered to the targeted region of the cell of interest.
  • the peptide can be cyclic(c) RGD, APRPG, NGR, F3 peptide, CGKRK, LyP-1, iRGD, iNGR, T7 peptide (HAIYPRH), MMP2-cleavable octapeptide (GPLGIAGQ), CP15 (VHLGYAT), FSH (FSH-b, 33-53 amino acids, YTRDLVKDPARPKIQKTCTF), LHRH (QHTSYkcLRP), gastrin-releasing peptides (GRPs) (CGGNHWAV GHLM), RVG (YTWMPENPRPGTPCDIFTNSRGKRASNG).
  • the targeting ligands can be incorporated into the bivalent or trivalent of homo- or hetero- peptide ligand combination in one system for better efficacy.
  • compositions that contain multivalent peptide components and siRNA, mRNA, or DNA, and that forms a nanoparticle.
  • the complex formation effectively protects and delivers the siRNA, mRNA, or DNA into the cell.
  • the nucleic acid is reversibly associated with the peptide carrier, which allows it to penetrate into the tumor specific cell and release the nucleic acid from the endosome to reach its target gene.
  • an siRNA delivery carrier as described herein may occur by combining a branched polypeptide (HKP), linear peptide (HKC) and siRNA and may be implemented by a method that includes the steps of: (a) preparing the positive charged linear peptide e.g. peptide HKC having a functional group for linkage a targeting group or other functional moiety; (b) attaching the targeting ligand to the linear peptide HKC through a covalent bond and recovery of the product; (c) stably combining a branched polypeptide (HKP), a linear peptide HKC carrying a targeting ligand in step (b), and siRNA to produce homogeneous nanoparticles.
  • a preparing the positive charged linear peptide e.g. peptide HKC having a functional group for linkage a targeting group or other functional moiety
  • attaching the targeting ligand to the linear peptide HKC through a covalent bond and recovery of the product
  • the steps may be also implemented at the same time , thereby allowing the preferable interaction and nanoparticle formation.
  • the plyometric nanoparticle by this method effectively forms a composite with various siRNAs in aqueous solution to form polynanoparticles, which may be selectively accumulated in a specific disease via the targeting effect.
  • the size of the polynanoparticle as described herein may range from 10 nm to 3000 nm based on the described production method. Depending on the preclinical study, the preferred size would be in 40 - 300 nm as determined by dynamic light scattering.
  • HKC polypeptide- nucleic acid delivery system described herein may be used as an effective ingredient of a pharmaceutical composition.
  • pharmaceutical compositions are provided that contain a therapeutically effective dose in a mix form of HKC peptide and nucleic acid. It may include one or more kinds of the pharmaceutical compatible polymers or carriers in addition to the HKC polypeptide - nucleic acid delivery system as described herein, together with methods for their administration.
  • the resulting product may be formulated in forms such as powder, liquid, solid state, capsule, injectable, or the like, which may be mixed with one or more effective ingredients such as saline solution, buffer solution, or other compatible ingredients to maintain the stability and effectiveness of the nucleic acid- peptide polynanoparticle.
  • effective ingredients such as saline solution, buffer solution, or other compatible ingredients to maintain the stability and effectiveness of the nucleic acid- peptide polynanoparticle.
  • compositions as described herein may be administered by standard methods, including oral or parenteral administration.
  • HKC 1 The designed peptide sequence of HKC 1 (sequence: KHHHKHHHKHHHKHHHKSSSC) was synthesized by solid state synthesizer as described in Figure 3.
  • the product was purified by the HPLC with water (0.065% TFA) and acetonitrile (0.05% TFA) and a chromatogram of HPLC in Figure 3A.
  • the structure of the H3K4C (in abbreviation HKC1) has one cysteine at the terminal site. The structure was further confirmed by the mass spectroscopy as shown in Figure 3B.
  • the second designed peptide sequence of HK2C (sequence: (KHHHKHHHKHHHKHHH)2KCSSC) was synthesized in a similar method by solid state synthesizer as shown in Figure 3B.
  • the third designed peptide sequence of HKC2 (sequence: KHHHKHHHKHHHKHHHKCSSC) was synthesized by solid state synthesis as described, for example, in US Pat. Nos. 7,070,807, 7,163,695 and 7,772,201.
  • FIG. 2 shows the general scheme for coupling.
  • functionalized PEG with a targeting motif is used for preparation of the H3K4C-PEG- targeting ligand functionalized polypeptide.
  • PEGs with targeting motifs such as folate, RGD, and/or monoclonal antibody, are commercially available or may be prepared in advance using methods that are well known in the art.
  • HKC bearing a terminal cysteine was conjugated with a maleimide functionalized PEG linked targeting motif such as (folate, RGD, mAh, etc.) through thiol/maleimide addition reaction under mild conditions as shown in Figure 2.
  • FIG. 4 shows the scheme for preparing HKC2-PEG1000-folate.
  • Folate-PEGIOOO-Mal (6.0 mg, 3.7 mmol) was dissolved in dry DMF (2.0 mL), followed by addition of trimethylamine (52 uL, 0.726 g/mL) in dry DMF.
  • the HKC (10.0 mg, 3.7 mmol) in a mixture of degassed water (100 ⁇ L) and DMF (300 ⁇ L) by soni cation and stirring was added to the mixture under the nitrogen at 25 °C.
  • HKC2-PEG-folate was characterized by 'H NMR in DMSO-d6, and the results are shown in Figure 5.
  • the sample of ⁇ 5 mg was dissolved in D2O or DMSO-d6 and the nmr spectra were recorded at 400 MHz. The three spectra were superimposed to clearly see the difference.
  • HKC2 in D 2 O was on the top
  • HKC2-PEG-folate in DMSO-d6 was at the middle
  • folate-PeglOOO-Mal was presented at the bottom.
  • the HKC was covalently coupled with folate-PeglOOO-Mal, and the characteristic signal of maleimide double bond at 7.0 ppm disappeared after reaction with cysteine.
  • the CH 2 proton of PEG group is present at the region 3.5ppm and peptide protons are located at 6.0 - 9.0 ppm in the HKC2-PEG-folate.
  • HKC2-PEG-folate was further characterized by UV/Vis spectroscopy and the result is shown in Figure 6.
  • the UV/Vis spectroscopy of HKC2-PEG-folate (top red curve) and Folate-PEG-Mal (bottom gray curve) were measured in water at room temperature.
  • the characteristic absorbance at the 220nm for the peptide and 275 nm for the folate was observed in the product spectrum.
  • First step coupling between c(RGDfk) and a bifunctional PEG molecule bearing N- hydroxy Succinimide (NHS) and Maleimide (Mai) functional groups, forming a amide bond via coupling between the amine and NHS ester.
  • c(RGDfk) (5.0 mg, 8.28 ⁇ mol) was dissolved in dry DMF (1 mL), and triethylamine (10 ⁇ L) was added. After the resulted mixture was stirred for 30 min at room temperature under the N2, the Mal-PEG2k-NHS (10 mg, 8.28 ⁇ mol) was added in one portion and stirred for 12 hours at 25 °C. The reaction mixture was poured into a cold diethyl ether (20 mL).
  • HKC2 (5.4 mg, 2.0 ⁇ mol) was dissolved in a mixture of DMF (0.6 mL) and degassed water (100 ⁇ L). The solution of HKC2 was added to the RGD- PEG2k-Mal (5.0 mg, 1.69 ⁇ mol) dissolved in dry DMF (1 mL) under stirring. Triethylamine (100 uL, 10 pg/ ⁇ L in dry DMF) was subsequently added and the mixture was stirred at 25 °C for 15 hours under N2.
  • the reaction mixture was poured into cold diethyl ether (20 mL). The mixture was centrifuged at 4000 rpm for 10 min at 5 °C, and the top clear supernatant was discarded. The crude product was dialyzed against water for 2 days with changes of water. After drying under vacuum, the product HKC2-PEG2k-RGD was afforded (7.1 mg, 75% yield). The product was characterized by spectroscopy method including 'H NMR (see Figure 10) and mass spectrometry.
  • Example 8 Preparation of HKC containing trivalent GalNAc ligand as HKC-PEGn- GalNAc.
  • the GalNAc3-PEG6-Mal (29.3 mg, 1.56 ⁇ mol) in dry DMF (300 ⁇ L) was added by springe needle to the HKC1 solution over 5 min. The resulting mixture was stirred under a nitrogen atmosphere for 16 hours. After HPLC monitoring showed that the starting material GalNAc was fully consumed, the crude product was purified using a Pierce Dextran desalting column to result the pure product GalNAc3-PEG6-HKCl as a white solid in 19 mg, 80% yield.
  • GalNAc-PEG12-HKCl and GalNAc-PEG24-HKCl were prepared in a similar method by replacing the GalNAc3-PEG6-Mal with the corresponding GalNAc-PEG12-Mal and GalNAc-PEG24-Mal. (reaction scheme shown in Figure 11).
  • Example 9 Formulation of HKC:HKP:TGFpi in the formation of nanoparticle and its size distribution.
  • HKP H3K4b. ( Figure 13).
  • the HKC2/HKP/siRNA was formulated in mass ratio 0:4:1, 1:4:1, 1:3:1, 2:3:1, 2:2:1, 3:1:1.
  • the resulted sample was subsequently measured by dynamic light scattering using a Nanoplus 90.
  • Example 10 Effect of treatment with Cell Death siRNA formulated with HKP alone or in combination with various amount of HKP and HKC2 on human glioblastoma T98G cells viability.
  • HKC2 160 ng/ ⁇ L
  • HKP 320 ng/pL
  • siRNA 80 ng/pL
  • aqueous solution of HKC2 160 ng/ ⁇ L
  • HKP 320 ng/pL
  • siRNA 80 ng/pL
  • HKC2/HKP/siRNA was formulated in mass ratio 0:4:1, 0:3:1, 1:3:1, 2:3:1, 0:2:1, 2:2:1
  • Transfection complexes were diluted with OPTI-MEM and added to the cells in 100 ⁇ L medium supplied with fresh medium. Transfection medium was replaced with 10% FBS/DMEM or EMEM after 6h.
  • Example 11 Effect of treatment with Cell Death siRNA formulated with HKP alone or in combination with various amounts of HKP and HKC2 on human hepatocellular carcinoma HepG2 cells viability.
  • aqueous solution of a mixture of HKC2 (160 ng/ ⁇ L), HKP (320 ng/ ⁇ L) and siRNA (80 ng/ ⁇ L) was mixed in a defined ratio (HKC2/HKP/siRNA was formulated in mass ratio 0:4:1, 0:3:1, 1:3:1, 2:3:1, 0:2:1, 2:2:1) and incubated at RT for 30 min.
  • Transfection complexes were diluted with OPTI-MEM and added to the cells in 100 pL medium supplied with fresh medium. Transfection medium was replaced with 10% FBS/DMEM or EMEM after 6h.
  • HKC2 in the formulation of 2:3:1 and 2:2: 1 showed comparable or even better cell death percentage in terms of the cell viability comparing to the control 0:3:1 and 0:2:1, although the overall cell viability is higher than the human glioblastoma T98G cell line study.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PCT/US2020/054251 2019-10-04 2020-10-05 Tumor-targeting polypeptide nanoparticle delivery system for nucleic acid therapeutics Ceased WO2021067930A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
BR112022006473A BR112022006473A2 (pt) 2019-10-04 2020-10-05 Sistema de administração em nanopartículas de polipeptídeo de direcionamento a tumor para agentes terapêuticos de ácido nucleico
AU2020357078A AU2020357078A1 (en) 2019-10-04 2020-10-05 Tumor-targeting polypeptide nanoparticle delivery system for nucleic acid therapeutics
IL291916A IL291916A (en) 2019-10-04 2020-10-05 A nanoparticulate delivery system containing tumor-targeting polypeptides for use as nucleic acid therapy
CN202080084185.2A CN115151278B (zh) 2019-10-04 2020-10-05 用于核酸疗法的靶向肿瘤的多肽纳米颗粒递送系统
JP2022520803A JP7644105B2 (ja) 2019-10-04 2020-10-05 核酸治療薬のための腫瘍標的化ポリペプチドナノ粒子送達システム
KR1020227014303A KR20220110174A (ko) 2019-10-04 2020-10-05 핵산 치료제를 위한 종양-표적화 폴리펩티드 나노입자 전달 시스템
CA3156823A CA3156823A1 (en) 2019-10-04 2020-10-05 Tumor-targeting polypeptide nanoparticle delivery system for nucleic acid therapeutics
EP20872228.0A EP4037716A4 (en) 2019-10-04 2020-10-05 TUMOR TARGETING POLYPEPTIDE NANOPARTICLE DELIVERY SYSTEM FOR NUCLEIC ACID THERAPEUTIC AGENTS
US17/713,037 US20220331441A1 (en) 2019-10-04 2022-04-04 Tumor-Targeting Polypeptide Nanoparticle Delivery System for Nucleic Acid Therapeutics
ZA2022/04734A ZA202204734B (en) 2019-10-04 2022-04-28 Tumor-targeting polypeptide nanoparticle delivery system for nucleic acid therapeutics

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962910760P 2019-10-04 2019-10-04
US62/910,760 2019-10-04
US201962915450P 2019-10-15 2019-10-15
US62/915,450 2019-10-15

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/713,037 Continuation US20220331441A1 (en) 2019-10-04 2022-04-04 Tumor-Targeting Polypeptide Nanoparticle Delivery System for Nucleic Acid Therapeutics

Publications (1)

Publication Number Publication Date
WO2021067930A1 true WO2021067930A1 (en) 2021-04-08

Family

ID=75337467

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/054251 Ceased WO2021067930A1 (en) 2019-10-04 2020-10-05 Tumor-targeting polypeptide nanoparticle delivery system for nucleic acid therapeutics

Country Status (11)

Country Link
US (1) US20220331441A1 (cg-RX-API-DMAC7.html)
EP (1) EP4037716A4 (cg-RX-API-DMAC7.html)
JP (1) JP7644105B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220110174A (cg-RX-API-DMAC7.html)
CN (1) CN115151278B (cg-RX-API-DMAC7.html)
AU (1) AU2020357078A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022006473A2 (cg-RX-API-DMAC7.html)
CA (1) CA3156823A1 (cg-RX-API-DMAC7.html)
IL (1) IL291916A (cg-RX-API-DMAC7.html)
WO (1) WO2021067930A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202204734B (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3801025A4 (en) * 2018-05-24 2022-03-09 Sirnaomics, Inc. Composition and methods of controllable co-coupling polypeptide nanoparticle delivery system for nucleic acid therapeutics
WO2023126297A1 (en) * 2021-12-30 2023-07-06 Byondis B.V. Antifolate linker-drugs and antibody-drug conjugates

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120158469A (zh) * 2025-05-19 2025-06-17 内蒙古大学 一种灌胃递送靶向编辑甲烷八叠球菌的牛甲烷减排方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011011631A2 (en) * 2009-07-22 2011-01-27 Samuel Zalipsky Nucleic acid delivery vehicles
US20120071540A1 (en) * 2008-12-31 2012-03-22 Lu Patrick Y Compositions and Methods Using siRNA Molecules and siRNA Cocktails for the Treatment of Breast Cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10501963A (ja) * 1994-04-15 1998-02-24 ターゲテッド ジェネティクス コーポレイション 遺伝子送達融合タンパク質
EP1817416A2 (en) * 2004-11-05 2007-08-15 Intradigm Corporation Compositions for treating respiratory viral infections and their use
EP1812016A4 (en) * 2004-11-17 2010-07-14 Univ Maryland HIGH-BRANCHED HK-PEPTIDES AS EFFECTIVE CARRIER FROM SIRNA
ES2545963T3 (es) * 2007-11-06 2015-09-17 Sirnaomics, Inc. Terapéutica con ARNi multidirigidos para la cicatrización de heridas de la piel sin cicatriz
CN102316858A (zh) * 2008-02-26 2012-01-11 阿帕玛生物科技公司 修饰过的可调的纳米粒子用于传递治疗,诊断,实验化合物及相关成分用于治疗用药
US11058779B2 (en) * 2015-09-08 2021-07-13 Sirnaomics, Inc. Sirna/nanoparticle formulations for treatment of middle-east respiratory syndrome coronaviral infection
CN107793388B (zh) * 2016-10-14 2021-06-11 长沙天赐生物医药科技有限公司 平板霉素类似物及其制备方法和应用
EP3532071A4 (en) * 2016-10-30 2020-09-02 Sirnaomics, Inc. PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE TO ACTIVATE HUMAN FIBROBLAST AND MYOFIBROBLAST APOPTOSIS
JP7512207B2 (ja) 2018-05-24 2024-07-08 サーナオミクス インコーポレイテッド 核酸治療薬のための調節可能な共カップリングポリペプチドナノ粒子送達系の組成物および方法
US20210180089A1 (en) * 2018-08-14 2021-06-17 Loxegen Holdings Pty Ltd Nanoparticles for transfection
WO2021061437A1 (en) 2019-09-12 2021-04-01 Sirnaomics, Inc. CO-DELIVERY OF TGF-β SIRNA AND PDL1 SIRNA TO TREAT CANCER

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120071540A1 (en) * 2008-12-31 2012-03-22 Lu Patrick Y Compositions and Methods Using siRNA Molecules and siRNA Cocktails for the Treatment of Breast Cancer
WO2011011631A2 (en) * 2009-07-22 2011-01-27 Samuel Zalipsky Nucleic acid delivery vehicles

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHOU ET AL.: "Selective modification of HK peptides enhances siRNA silencing of tumor targets in vivo", CANCER GENE THERAPY, vol. 18, 2011, pages 707 - 716, XP055685868, DOI: 10.1038/cgt.2011.40 *
VAN ROSMALEN ET AL.: "Tuning the Flexibility of Glycine-Serine Linkers To Allow Rational Design of Multidomain Proteins", BIOCHEMISTRY, vol. 56, 2017, pages 6565 - 65, XP055813760 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3801025A4 (en) * 2018-05-24 2022-03-09 Sirnaomics, Inc. Composition and methods of controllable co-coupling polypeptide nanoparticle delivery system for nucleic acid therapeutics
WO2023126297A1 (en) * 2021-12-30 2023-07-06 Byondis B.V. Antifolate linker-drugs and antibody-drug conjugates

Also Published As

Publication number Publication date
JP2022550901A (ja) 2022-12-05
CN115151278B (zh) 2025-08-22
BR112022006473A2 (pt) 2022-07-05
EP4037716A4 (en) 2023-05-03
US20220331441A1 (en) 2022-10-20
CA3156823A1 (en) 2021-04-08
AU2020357078A1 (en) 2022-05-26
ZA202204734B (en) 2024-09-25
EP4037716A1 (en) 2022-08-10
IL291916A (en) 2022-06-01
JP7644105B2 (ja) 2025-03-11
KR20220110174A (ko) 2022-08-05
CN115151278A (zh) 2022-10-04

Similar Documents

Publication Publication Date Title
KR100883471B1 (ko) siRNA의 세포내 전달을 위한 siRNA와 친수성 고분자 간의접합체 및 그의 제조방법
Gooding et al. Synthesis and characterization of rabies virus glycoprotein-tagged amphiphilic cyclodextrins for siRNA delivery in human glioblastoma cells: in vitro analysis
US20220331441A1 (en) Tumor-Targeting Polypeptide Nanoparticle Delivery System for Nucleic Acid Therapeutics
US20080112916A1 (en) CHEMICALLY MODIFIED POLYCATION POLYMER FOR siRNA DELIVERY
Schroeder et al. Alkane-modified short polyethyleneimine for siRNA delivery
JP2010526091A5 (cg-RX-API-DMAC7.html)
MXPA04005194A (es) Compolimero soluble en agua policationico y metodo para transferir macromoleculas polianionicas a traves de barreras biologicas.
CN102027043A (zh) 生物可降解的交联支链聚(亚烷基亚胺)
JP2010526091A (ja) 癌の処置のための生物学的な標的基の改変
MX2012011515A (es) Entidades quimicas simples novedosas y metodos de suministro de oligonucleotidos.
KR101445265B1 (ko) 히알루론산-핵산 접합체 및 이를 포함하는 핵산 전달용 조성물
Tang et al. Synergistic targeted delivery of payload into tumor cells by dual-ligand liposomes co-modified with cholesterol anchored transferrin and TAT
WO2011154331A1 (en) Polymers for delivery of nucleic acids
WO2008042686A2 (en) Multifunctional carriers for the delivery of nucleic acids and methods of use thereof
WO1998046274A2 (en) Cationic polymers for nucleic acid transfection
Kano et al. Grafting of poly (ethylene glycol) to poly-lysine augments its lifetime in blood circulation and accumulation in tumors without loss of the ability to associate with siRNA
CA2587962A1 (en) Highly branched hk peptides as effective carriers of sirna
WO2019063705A1 (en) CANCER OF THE PROSTATE RESISTANT TO CASTRATION
CN114392358A (zh) 一种肿瘤靶向的核酸适体药物偶连物
KR20220030204A (ko) 치료 분자의 표적화된 전달
Zhang et al. A zwitterionic polymer-inspired material mediated efficient CRISPR-Cas9 gene editing
JP2022550901A5 (cg-RX-API-DMAC7.html)
MXPA01012802A (es) Copolimeros para el transporte de acidos nucleicos a las celulas.
EP4228671A1 (en) Linker compounds comprising amide bonds
Kos et al. Gene transfer with sequence-defined oligo (ethanamino) amides bioreducibly attached to a propylenimine dendrimer core

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20872228

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2022520803

Country of ref document: JP

Kind code of ref document: A

Ref document number: 3156823

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112022006473

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2020872228

Country of ref document: EP

Effective date: 20220504

ENP Entry into the national phase

Ref document number: 2020357078

Country of ref document: AU

Date of ref document: 20201005

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112022006473

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20220404

WWW Wipo information: withdrawn in national office

Ref document number: 2020872228

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 202080084185.2

Country of ref document: CN